Mark Agulnik, MD, and Daniel Wang, MD, discuss risk assessment and treatment approaches with systemic therapy for desmoid tumors.
Daniel Wang, MD
Advertisement
Daniel Wang, MD, is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center.
Articles by Daniel Wang, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Tumors
3
Analyses Support Integrating MRD and Genomic Features in Prognosis of Multiple Myeloma
4
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
5